CARISOPRODOL COMPOUND Drug Patent Profile

When do Carisoprodol Compound patents expire, and what generic alternatives are available?

Carisoprodol Compound is a drug marketed by Watson Labs and is included in one NDA.

The generic ingredient in CARISOPRODOL COMPOUND is aspirin; carisoprodol. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; carisoprodol profile page.

Summary for CARISOPRODOL COMPOUND

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	CARISOPRODOL COMPOUND at DailyMed

US Patents and Regulatory Information for CARISOPRODOL COMPOUND

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	CARISOPRODOL COMPOUND	aspirin; carisoprodol	TABLET;ORAL	088809-001	Oct 3, 1985		DISCN	No	No

Carisoprodol Compound Market Dynamics, Patent Status, and Financial Trajectory

Last updated: August 7, 2026

Carisoprodol compound is a legacy combination product category centered on carisoprodol, usually combined with aspirin and, in some products, codeine. Its commercial market is small, mature, and fragmented. The principal constraints are controlled-substance regulation, limited clinical differentiation, generic substitution, low reimbursement value, and declining physician use of carisoprodol. No public company reports standalone revenue for carisoprodol compound, so financial analysis must rely on market structure, prescription trends, product availability, and regulatory exposure rather than audited product sales.

What is carisoprodol compound?

Carisoprodol compound products combine the centrally acting skeletal-muscle relaxant carisoprodol with one or more analgesic ingredients.

Product category	Typical active ingredients	Commercial position
Carisoprodol and aspirin	Carisoprodol plus aspirin	Legacy muscle-relaxant and analgesic combination
Carisoprodol, aspirin, and codeine	Carisoprodol plus aspirin and codeine phosphate	More tightly controlled combination with opioid exposure
Single-ingredient carisoprodol	Carisoprodol only	Larger generic market and principal competitive substitute
Other muscle-relaxant products	Cyclobenzaprine, methocarbamol, tizanidine, baclofen	Main therapeutic competitors

The term “carisoprodol compound” does not identify one globally standardized product. In the United States, it commonly refers to combination tablets historically marketed under Soma Compound or Soma Compound with Codeine-type naming. Product composition, manufacturer, labeling, and availability can differ by jurisdiction.

Carisoprodol is metabolized to meprobamate, a compound associated with sedative, abuse, dependence, and withdrawal risks. The FDA approved carisoprodol for short-term treatment of acute, painful musculoskeletal conditions, generally for periods of up to two or three weeks. The FDA label states that effectiveness beyond this period has not been established.[1]

What is the FDA regulatory status of carisoprodol compound?

Carisoprodol is an FDA-approved prescription drug, but the regulatory status of specific combination products depends on the individual formulation and manufacturer.

The key regulatory points are:

• Carisoprodol is a federally controlled substance classified as Schedule IV under the Controlled Substances Act.
• Codeine-containing carisoprodol combinations face additional opioid controls. Federal scheduling depends on the codeine concentration and formulation.
• The FDA-approved use is short-term relief of acute musculoskeletal pain and associated muscle spasm.
• The FDA label warns about sedation, impaired driving, abuse, dependence, and withdrawal.
• The combination with aspirin creates additional gastrointestinal bleeding and salicylate-toxicity risks.
• The combination with codeine adds respiratory-depression, overdose, misuse, and opioid-withdrawal risks.[1][2]

The FDA has not established a separate modern therapeutic category for “carisoprodol compound.” Each product is regulated through its own approved drug application, labeling, manufacturing controls, and post-market safety obligations.

What is the Orange Book status of carisoprodol compound?

The Orange Book is relevant to approved prescription drug products, their therapeutic-equivalence evaluations, and listed patent or exclusivity information. Carisoprodol compound products are legacy products whose original market protection has long expired or is no longer commercially significant.

The commercial implications are:

1. No current new-molecule exclusivity supports the category.
2. Any original formulation or composition patents would generally have expired after decades of commercial availability.
3. Generic competition, rather than patent protection, determines pricing.
4. Product-level Orange Book listings can change as manufacturers enter, discontinue, or update applications.
5. Combination products containing codeine may have fewer active suppliers because of controlled-substance compliance and demand constraints.

The Orange Book does not provide a durable patent-based barrier comparable with newer branded medicines.[3]

When does carisoprodol compound lose exclusivity?

Carisoprodol compound lost practical market exclusivity many years ago. The underlying active ingredients are old, and the products have been available long enough that original composition, formulation, and use patents are not meaningful commercial barriers.

A typical U.S. exclusivity timeline is:

Protection category	Status for carisoprodol compound
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not a current commercial barrier
Original composition patents	Expired
Original method-of-use patents	Expired or commercially irrelevant
Formulation patents	No material category-wide barrier identified
Generic competition	Established or readily available for related carisoprodol products

The most important protection available to a manufacturer is operational rather than legal. A supplier may gain temporary commercial advantage through an approved formulation, reliable controlled-substance quota, manufacturing capacity, wholesaler access, or a shortage-related supply position. Those advantages do not create patent exclusivity.

What patents protect carisoprodol compound?

No active patent estate appears to provide meaningful protection for the legacy carisoprodol compound market. The relevant intellectual-property position is weak for five reasons:

• Carisoprodol was introduced decades ago.
• Aspirin and codeine are long-established active ingredients.
• The combination concepts are old.
• Generic products have competed for years.
• Commercial buyers generally treat the product as an interchangeable or near-interchangeable generic medicine.

What formulations are protected by carisoprodol compound patents?

Historical patents may have addressed tablet composition, dosage ratios, excipients, or manufacturing processes. Those rights are unlikely to constrain current U.S. entry because patent terms have expired or because equivalent products can be designed around them.

The highest practical formulation risk is regulatory, not patent-based. A manufacturer must demonstrate that its product conforms to the approved formulation, strength, dissolution profile, labeling, and quality standards. For codeine-containing products, controlled-substance manufacturing, security, recordkeeping, and distribution requirements create a higher operating burden.

How strong is the patent estate for carisoprodol compound?

The patent estate is weak.

Patent factor	Assessment
Composition-of-matter protection	None of current commercial significance
Formulation protection	Low
Method-of-use protection	Low
Manufacturing-process protection	Low to moderate at most, depending on process
Orange Book litigation leverage	Low
Freedom-to-operate risk	Generally low for standard generic formulations
Regulatory execution risk	Moderate
Controlled-substance supply risk	Moderate to high for codeine products

A new entrant is more likely to encounter FDA approval, manufacturing, quota, and distribution problems than a blocking patent.

Which companies are challenging carisoprodol compound exclusivity?

No major current Paragraph IV campaign defines the carisoprodol compound market. The product category is too mature to support a conventional branded-versus-generic patent contest.

Paragraph IV litigation is generally associated with an active branded product protected by unexpired Orange Book patents. Carisoprodol compound does not have the commercial profile of a product with substantial remaining patent life or high expected generic-entry value. Challenges, if filed against a particular product, would be product-specific and would not establish category-wide exclusivity.

The competitive field is more likely to include generic manufacturers, specialty pharmaceutical suppliers, repackagers, and contract manufacturers than large innovative pharmaceutical companies.

What generic entry risks exist for carisoprodol compound?

Generic entry risk is high, but the financial impact is limited because the market is already genericized.

A new entrant could affect incumbent suppliers through:

• Lower contract and wholesale pricing.
• Increased substitution at pharmacies.
• Loss of preferred wholesaler position.
• Inventory pressure for small suppliers.
• Reduced margins on low-volume combination tablets.
• Greater price competition during temporary supply shortages.

For codeine-containing formulations, generic entry may be slower than for single-ingredient carisoprodol because manufacturers must manage opioid controls, quota allocation, diversion monitoring, and more complex distribution requirements. That friction can preserve short-term supplier margins, but it does not create durable exclusivity.

What is the competitive landscape for carisoprodol compound?

The main competitive threat is substitution, not direct product rivalry.

Competitor	Relative market threat	Reason
Generic carisoprodol	High	Same core muscle-relaxant ingredient without combination complexity
Cyclobenzaprine	High	Widely used alternative for acute muscle spasm
Methocarbamol	High	Broad generic availability and lower controlled-substance exposure
Tizanidine	Moderate	Useful in spasticity and muscle-spasm indications
Baclofen	Moderate	Established use, particularly for spasticity
NSAID plus muscle relaxant	Moderate	Replaces separate analgesic and muscle-relaxant therapy
Opioid-containing products	Variable	Compete in pain treatment but face stronger opioid restrictions

Clinical guidelines and payer policies often favor non-opioid approaches, physical therapy, NSAIDs, or alternative muscle relaxants. Carisoprodol’s abuse and sedation profile limits its use relative to non-controlled alternatives.

How does carisoprodol compound compare with single-ingredient carisoprodol?

Single-ingredient carisoprodol has a broader commercial base and simpler manufacturing profile.

Metric	Carisoprodol compound	Single-ingredient carisoprodol
Product complexity	Higher	Lower
Aspirin-related safety exposure	Present in aspirin combinations	Absent
Opioid controls	Present in codeine products	Absent
Prescribing flexibility	Lower	Higher
Generic supply pool	Smaller	Broader
Patent barrier	Minimal	Minimal
Pricing power	Low	Low
Regulatory burden	Higher for codeine products	Moderate

Combination products can offer convenience when analgesia and muscle relaxation are prescribed together. That advantage is limited by fixed dosing, contraindications, and the availability of separate generic products.

What is the financial trajectory for carisoprodol compound?

The financial trajectory is mature to declining, with limited visibility into standalone revenue.

Revenue exposure

Manufacturers generally do not report carisoprodol compound revenue separately. Public filings usually aggregate the product within generic pharmaceuticals, specialty products, or other prescription medicines. No reliable standalone market-capitalization or revenue multiple can therefore be assigned to the product.

The revenue model has four characteristics:

1. Low unit pricing.
2. High generic substitution.
3. Small addressable patient population relative to single-ingredient alternatives.
4. Limited ability to raise price without losing formulary and pharmacy volume.

Margin profile

Gross margins can vary materially by supplier. A manufacturer with an established tablet line, controlled-substance infrastructure, and stable raw-material supply may earn acceptable contribution margins. A new entrant faces lower economics because of:

• FDA application and validation costs.
• Controlled-substance compliance systems.
• Low annual volume.
• Distributor fees.
• Pharmacovigilance and recall obligations.
• Price competition from established generic suppliers.

The codeine combination may carry a higher nominal price than aspirin-only carisoprodol products, but its additional regulatory and supply costs can offset that advantage.

Financial outlook

Period	Expected market behavior
Historical period	Brand-to-generic erosion and broad substitution
Current mature phase	Low growth, fragmented supply, limited pricing power
Near term	Stable-to-declining demand with episodic supply disruptions
Longer term	Further contraction as prescribers favor non-controlled alternatives

A temporary revenue increase is possible for a supplier that gains market share during a shortage or after competitor discontinuation. Such gains would be supply-driven rather than evidence of durable product expansion.

What patent litigation affects carisoprodol compound?

No major active patent litigation is central to the category. Litigation exposure is more likely to arise from:

• Product-liability claims involving sedation, dependence, or overdose.
• Opioid-related compliance and diversion investigations.
• Manufacturing or quality disputes.
• False-claims or controlled-substance distribution matters.
• Trademark disputes involving legacy brand names.

Patent litigation is unlikely to produce a significant change in market structure unless a specific manufacturer asserts a later-developed formulation or process patent against a particular competitor. That would not necessarily affect the broader carisoprodol compound market.

What geographic coverage applies to carisoprodol compound?

The United States is the most commercially relevant market for the branded and generic carisoprodol products discussed here. International availability varies substantially.

• Carisoprodol is controlled or restricted in several jurisdictions.
• Some countries do not approve carisoprodol or have withdrawn it because of abuse and dependence concerns.
• Codeine controls differ by country.
• Product names and combination strengths are not globally consistent.
• Patent risk is minimal in mature markets, but regulatory approval and controlled-substance rules remain jurisdiction-specific.

A manufacturer pursuing international expansion would face a regulatory-market-access project rather than a patent-expansion project.

What manufacturing and IP barriers exist?

The principal barriers are manufacturing and compliance execution.

A supplier needs:

• FDA-compliant tablet manufacturing.
• Validated assay, dissolution, content-uniformity, and stability methods.
• Reliable sources of carisoprodol, aspirin, and, where relevant, codeine.
• Controlled-substance registrations and security procedures.
• Distribution controls and suspicious-order monitoring.
• Pharmacovigilance systems for sedation, misuse, and overdose events.
• Labeling that accurately reflects short-term use and safety warnings.

These barriers can reduce the number of active suppliers even when patents do not. The result is a market with low legal exclusivity but occasional supply concentration.

Key Takeaways

• Carisoprodol compound is a mature generic combination market, not an active innovation market.
• The term generally covers carisoprodol with aspirin, or carisoprodol with aspirin and codeine.
• Original composition, method-of-use, and formulation exclusivity has expired or lacks commercial relevance.
• The Orange Book does not provide a meaningful current patent barrier for the category.
• Paragraph IV litigation is not a major driver of competition.
• Codeine-containing products face higher regulatory and supply burdens than single-ingredient carisoprodol.
• Revenue is not publicly reported on a standalone basis.
• The financial outlook is stable to declining, with limited pricing power.
• Substitution by cyclobenzaprine, methocarbamol, tizanidine, baclofen, and non-opioid treatment is the main commercial risk.
• Manufacturing capacity, controlled-substance compliance, and distribution access matter more than patents.

FAQs

Is carisoprodol compound still commercially available?

Availability depends on the specific formulation, manufacturer, and market. Single-ingredient carisoprodol has broader generic availability than aspirin- or codeine-containing combinations.

Is carisoprodol compound a controlled substance?

Carisoprodol is Schedule IV federally in the United States. Products containing codeine face additional controlled-substance requirements, with scheduling dependent on formulation and strength.

Can a generic manufacturer launch carisoprodol compound without a patent risk?

Patent risk is generally low for standard legacy formulations. The main launch risks are FDA approval, bioequivalence, manufacturing validation, controlled-substance compliance, and commercial scale.

Why is carisoprodol compound less attractive than generic carisoprodol?

The combination has a smaller market, more complex dosing, greater safety exposure, and, for codeine products, additional opioid controls. Those factors increase operating costs without creating durable pricing power.

Does carisoprodol compound have biosimilar competition?

No. Carisoprodol compound is a chemically synthesized small-molecule drug, not a biologic. Competition occurs through generic-drug pathways rather than biosimilar approval pathways.

References

1. U.S. Food and Drug Administration. (2010). Soma (carisoprodol) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (2013). FDA Drug Safety Communication: FDA approves new labeling for extended-release and immediate-release opioid analgesics. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Drug Enforcement Administration. (n.d.). Controlled substances schedules. U.S. Department of Justice. https://www.dea.gov/drug-information/drug-scheduling

5. U.S. Food and Drug Administration. (n.d.). Carisoprodol compound product labeling and prescription drug databases. FDA. https://www.accessdata.fda.gov/